ArticleMolecular therapy. Nucleic acids2026
Characterization of RNA using mass photometry: Method and technical perspectives.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing analytical methods for RNA-based products, such as mRNA vaccines, requires tools that support release testing, stability assessment, and characterization. Mass photometry (MP) is a label-free, single-molecule technique increasingly applied to biotherapeutics and vaccines. Here, we outline best practices and technical considerations for using MP to analyze vaccine mRNA constructs and other RNA samples. With appropriate calibration, MP provides mRNA molecular weight and quantifies heterogeneous species, including those difficult to resolve using traditional techniques. We systematically evaluated experimental parameters influencing RNA measurements, including surface chemistry and buffer composition, and show that cationic-coated sample carriers and salt-containing buffers are essential for reproducible detection and mass resolution. Low-mass species were assessed using multiple mRNA constructs, kinetic analysis, and buffer controls to distinguish genuine sample heterogeneity from method artifacts. We further examined the effects of ionic additives on oligomeric species. MP results were compared with charge detection mass spectrometry and fragment analyzer measurements, showing good agreement when accounting for differences in measurement principles. Overall, MP provides a rapid, low-sample consumption, and information-rich approach for mRNA characterization and quality assessment, either as a standalone method or as an orthogonal complement to established RNA analytical techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.